NEW YORK (GenomeWeb News) – Molecular diagnostics firm Provista Diagnostics today announced the completion of a Series B financing round that raised $6 million.

Existing investors participated in the round, which will be used to expand the company's commercial market development of dtectDx-Breast as Provista pursues 510(k) clearance of the assay. The firm also plans to conduct additional clinical trials for the test, which detects blood-based protein biomarkers that are "highly associated" with the development of breast cancer, it said on its website.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.